Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27995059 | 1.00 | ALDH1A1 (0.65) | ALDH1A1TSHRDNM1SMN1; SMN2L3MBTL1 | |
| SCHEMBL19909604 | 0.97 | ALDH1A1 (0.59) | ALDH1A1TSHRDNM1SMN1; SMN2L3MBTL1 | |
| SCHEMBL542772 | 0.91 | ALDH1A1 (0.50) | ALDH1A1TSHRDNM1SMN1; SMN2L3MBTL1 | |
| SCHEMBL4672998 | 0.91 | ALDH1A1 (0.50) | ALDH1A1TSHRDNM1SMN1; SMN2L3MBTL1 | |
| Bromide SCHEMBL10492652 | 0.88 | DNM1 (0.50) | ALDH1A1TSHRDNM1SMN1; SMN2L3MBTL1 | |
| SCHEMBL14666299 | 0.88 | ALDH1A1 (0.47) | ALDH1A1TSHRDNM1SMN1; SMN2L3MBTL1 | |
| SCHEMBL2564528 | 0.87 | SIGMAR1 (0.46) | ALDH1A1TSHRDNM1SIGMAR1HRH4 | |
| SCHEMBL2142541 | 0.87 | SIGMAR1 (0.46) | ALDH1A1TSHRDNM1SIGMAR1HRH4 | |
| SCHEMBL2137948 | 0.87 | SIGMAR1 (0.46) | ALDH1A1TSHRDNM1SIGMAR1HRH4 | |
| SCHEMBL2141035 | 0.87 | SIGMAR1 (0.46) | ALDH1A1TSHRDNM1SIGMAR1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250183340-A1 | MEMBRANE ELECTRODE ASSEMBLIES USING ANION EXCHANGE MEMBRANES AND ANION EXCHANGE POLYMERS | USA FORTESCUE IP INC (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250075029-A1 | POLYCYLOOLEFINIC POLYMERS AND ANION EXCHANGE MEMBRANES DERIVED THEREFROM | PROMERUS, LLC (US) | 2025-03-06 | — | — | US | disclosed |
| US-12180329-B2 | Polycyloolefinic polymers and anion exchange membranes derived therefrom | PROMERUS, LLC (US) | 2024-12-31 | — | — | US | disclosed |
| US-20240124641-A1 | POLYCYLOOLEFINIC POLYMERS AND ANION EXCHANGE MEMBRANES DERIVED THEREFROM | PROMERUS, LLC (US) | 2024-04-18 | — | — | US | disclosed |
| US-11879033-B2 | Polycyloolefinic polymers and anion exchange membranes derived therefrom | PROMERUS, LLC (US) | 2024-01-23 | — | — | US | disclosed |
| EP-4188980-A1 | POLYCYLOOLEFINIC POLYMERS AND ANION EXCHANGE MEMBRANES DERIVED THEREFROM | Promerus, LLC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-2785435-B1 | METHOD FOR ELIMINATING ACID COMPOUNDS FROM A GASEOUS EFFLUENT WITH AN ABSORBENT SOLUTION MADE FROM BIS(AMINO-3-PROPYL)ETHERS OR (AMINO-2-ETHYL)-(AMINO-3-PROPYL)ETHERS | IFP ENERGIES NOW (FR) | 2018-02-28 | — | — | EP | disclosed |
| EP-1707263-B1 | Catalyst composition comprising an alkylene diamine-nickel complex and process for producing a cross-coupled compound using the same | TOSOH CORP (JP) | 2009-02-25 | — | — | EP | disclosed |
| US-20060224011-A1 | Catalyst composition and process for producing cross-coupled compound using same | TOSOH CORPORATION | 2006-10-05 | — | — | US | disclosed |
| EP-1707263-A1 | Catalyst composition comprising an alkylene diamine-nickel complex and process for producing a cross-coupled compound using the same | Tosoh Corporation (JP) | 2006-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060224011-A1 | Catalyst composition and process for producing cross-coupled compound using same | C5, TST, PYM1 | ALDH1A1 4510/4885TSHR 87/4885DNM1 2316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.